Discovery of Novel Cannabinoid Receptor Ligands from Diverse Marine Organisms

Soderstrom, Ken; Murray, Thomas F.; Yoo, Hye‐Dong; Ketchum, Sharon O.; Milligan, Ken; Gerwick, William H.; Ortega, Marı́a J.; Salvá, Javier

doi:10.1007/978-1-4899-1810-9_14

Cited by 7 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Grenadamide, a PUFA in Lyngbya majuscula , has micromolar affinities for CB 1 [181]. Soderstrom et al [182] extracted but did not identify an eCB-like compound from L. majuscula . Soderstrom also extracted a dozen eCB-like PUFAs from unidentified green algae (Chlorophyta), the brown alga Laminaria angustata , and the sponge Mycale micracanthoxea .…”

Section: Resultsmentioning

confidence: 99%

Care and Feeding of the Endocannabinoid System: A Systematic Review of Potential Clinical Interventions that Upregulate the Endocannabinoid System

2014

View full text Add to dashboard Cite

BackgroundThe “classic” endocannabinoid (eCB) system includes the cannabinoid receptors CB1 and CB2, the eCB ligands anandamide (AEA) and 2-arachidonoylglycerol (2-AG), and their metabolic enzymes. An emerging literature documents the “eCB deficiency syndrome” as an etiology in migraine, fibromyalgia, irritable bowel syndrome, psychological disorders, and other conditions. We performed a systematic review of clinical interventions that enhance the eCB system—ways to upregulate cannabinoid receptors, increase ligand synthesis, or inhibit ligand degradation.Methodology/Principal FindingsWe searched PubMed for clinical trials, observational studies, and preclinical research. Data synthesis was qualitative. Exclusion criteria limited the results to 184 in vitro studies, 102 in vivo animal studies, and 36 human studies. Evidence indicates that several classes of pharmaceuticals upregulate the eCB system, including analgesics (acetaminophen, non-steroidal anti-inflammatory drugs, opioids, glucocorticoids), antidepressants, antipsychotics, anxiolytics, and anticonvulsants. Clinical interventions characterized as “complementary and alternative medicine” also upregulate the eCB system: massage and manipulation, acupuncture, dietary supplements, and herbal medicines. Lifestyle modification (diet, weight control, exercise, and the use of psychoactive substances—alcohol, tobacco, coffee, cannabis) also modulate the eCB system.Conclusions/SignificanceFew clinical trials have assessed interventions that upregulate the eCB system. Many preclinical studies point to other potential approaches; human trials are needed to explore these promising interventions.

show abstract

Section: Resultsmentioning

confidence: 99%

Care and Feeding of the Endocannabinoid System: A Systematic Review of Potential Clinical Interventions that Upregulate the Endocannabinoid System

2014

View full text Add to dashboard Cite

show abstract

“…10 Our group has previously reported cannabinomimetic activity for the chlorosulfolipid malhamensilipin A, 10c as well as the fatty acid-based metabolites grenadadiene 10d and semiplenamides A, B and G. 10e …”

mentioning

confidence: 99%

Cannabinomimetic Lipid from a Marine Cyanobacterium

et al. 2011

View full text Add to dashboard Cite

NMR-guided fractionation of two independent collections of the marine cyanobacteria Lyngbya majuscula obtained from Papua New Guinea and Oscillatoria sp. collected in Panama led to the isolation of the new lipids, serinolamide A (3) and propenediester (4). Their structures were determined by NMR and MS data analysis. Serinolamide A (3) exhibited a moderate agonist effect and selectivity for the CB1 cannabinoid receptor (EC50 2.3 µM, >10-fold), and represents the newest addition to the known cannabinomimetic natural products of marine origin.

show abstract

“…In preliminary studies, they appear inactive on CB 1 , CB 2 , and TRPV1 receptors. Soderstrom et al [ 115 ] also extracted numerous endocannabinoid-like purified unsaturated fatty acids from green algae (Chlorophyta), the brown alga Laminaria angustata , and the sponge Mycale micracanthoxea . The authors did not find endocannabinoid compound from L. majuscula .…”

Section: Phytochemicals As Lead Compounds Targeting Ecsmentioning

confidence: 99%

Small Molecules from Nature Targeting G-Protein Coupled Cannabinoid Receptors: Potential Leads for Drug Discovery and Development

Sharma

Sadek

Goyal

et al. 2015

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

The cannabinoid molecules are derived from Cannabis sativa plant which acts on the cannabinoid receptors types 1 and 2 (CB1 and CB2) which have been explored as potential therapeutic targets for drug discovery and development. Currently, there are numerous cannabinoid based synthetic drugs used in clinical practice like the popular ones such as nabilone, dronabinol, and Δ9-tetrahydrocannabinol mediates its action through CB1/CB2 receptors. However, these synthetic based Cannabis derived compounds are known to exert adverse psychiatric effect and have also been exploited for drug abuse. This encourages us to find out an alternative and safe drug with the least psychiatric adverse effects. In recent years, many phytocannabinoids have been isolated from plants other than Cannabis. Several studies have shown that these phytocannabinoids show affinity, potency, selectivity, and efficacy towards cannabinoid receptors and inhibit endocannabinoid metabolizing enzymes, thus reducing hyperactivity of endocannabinoid systems. Also, these naturally derived molecules possess the least adverse effects opposed to the synthetically derived cannabinoids. Therefore, the plant based cannabinoid molecules proved to be promising and emerging therapeutic alternative. The present review provides an overview of therapeutic potential of ligands and plants modulating cannabinoid receptors that may be of interest to pharmaceutical industry in search of new and safer drug discovery and development for future therapeutics.

show abstract

Discovery of Novel Cannabinoid Receptor Ligands from Diverse Marine Organisms

Cited by 7 publications

References 5 publications

Care and Feeding of the Endocannabinoid System: A Systematic Review of Potential Clinical Interventions that Upregulate the Endocannabinoid System

Care and Feeding of the Endocannabinoid System: A Systematic Review of Potential Clinical Interventions that Upregulate the Endocannabinoid System

Cannabinomimetic Lipid from a Marine Cyanobacterium

Small Molecules from Nature Targeting G-Protein Coupled Cannabinoid Receptors: Potential Leads for Drug Discovery and Development

Contact Info

Product

Resources

About